Boehringer Ingelheim India signs MoU with NIPER

Hyderabad: Boehringer Ingelheim India Private Limited today signed two separate Memoranda of Understanding with the National Institutes of Pharmaceutical Education and Research at Ahmedabad and at Hyderabad. The two five-year agreements were signed at a joint ceremony in Hyderabad and establish a framework to advance pharmaceutical research, education and innovation through joint research initiatives, academic exchange and capability-building programmes.

The MoU signing ceremony witnessed presence of Dr. Shailendra Saraf, Director, NIPER-Ahmedabad and Hyderabad along with Dr. Srinivas Nanduri, Professor & Dean and Dr. Jitender Madan, Professor from NIPER Hyderabad. Under the terms of the Memoranda, Boehringer Ingelheim India will enable researchers and faculty at both institutes to access opnMe® (www.opnme.com), the company’s global open science portal.

Through opnMe®, the same molecules that scientists across the world use to ask new questions in early biology will now be in the hands of researchers in Gandhinagar. This is how a manufacturing state grows into a discovery state. And Biopharma SHAKTI has placed biologics at the centre of India’s next pharmaceutical chapter, with this partnership with the NIPER, Hyderabad positioned exactly there.

Boehringer Ingelheim has already shared more than 150 molecules with Indian institutions through opnMe®, and the new collaborations extend this access to two of the country’s most established pharmaceutical and life sciences ecosystems on the same day.The collaboration with NIPER, Hyderabad strengthens the research and talent foundation of an ecosystem that is central to India’s biopharmaceutical ambitions. These two MoUs build on the partnerships signed earlier in 2026 with the institutes at Raebareli and Hajipur. With these new agreements, Boehringer Ingelheim India’s open science collaboration now extends across northern, eastern, western and southern India.